###begin article-title 0
###xml 87 95 <span type="species:ncbi:9606">patients</span>
Increased expression of vascular endothelin type B and angiotensin type 1 receptors in patients with ischemic heart disease
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 61 69 <span type="species:ncbi:9606">Patients</span>
###xml 323 331 <span type="species:ncbi:9606">patients</span>
Endothelin-1 and angiotensin II are strong vasoconstrictors. Patients with ischemic heart disease have elevated plasma levels of endothelin-1 and angiotensin II and show increased vascular tone. The aim of the present study was to examine the endothelin and angiotensin II receptor expression in subcutaneous arteries from patients with different degrees of ischemic heart disease.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 334 335 334 335 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A</sub>
###xml 351 352 351 352 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 381 382 381 382 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 398 399 398 399 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 494 503 494 503 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 70 78 <span type="species:ncbi:9606">patients</span>
###xml 178 186 <span type="species:ncbi:9606">patients</span>
Subcutaneous arteries were obtained, by biopsy from the abdomen, from patients undergoing coronary artery bypass graft (CABG) surgery because of ischemic heart disease (n = 15), patients with angina pectoris without established myocardial infarction (n = 15) and matched cardiovascular healthy controls (n = 15). Endothelin type A (ETA) and type B (ETB), and angiotensin type 1 (AT1) and type 2 (AT2) receptors expression and function were examined using immunohistochemistry, Western blot and in vitro pharmacology.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 2 4 2 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A </sub>
###xml 31 33 31 33 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 124 126 124 126 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 474 476 468 470 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 590 592 584 586 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A </sub>
###xml 605 607 599 601 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 634 636 628 630 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 721 723 715 717 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 926 928 914 916 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 160 168 <span type="species:ncbi:9606">patients</span>
###xml 229 237 <span type="species:ncbi:9606">patients</span>
###xml 392 400 <span type="species:ncbi:9606">patients</span>
###xml 823 831 <span type="species:ncbi:9606">patients</span>
###xml 1081 1089 <span type="species:ncbi:9606">patients</span>
ETA and, to a lesser extent, ETB receptor staining was observed in the healthy vascular smooth muscle cells. The level of ETB receptor expression was higher in patients undergoing CABG surgery (250% +/- 23%; P < 0.05) and in the patients with angina pectoris (199% +/- 6%; P < 0.05), than in the healthy controls (100% +/- 28%). The data was confirmed by Western blotting. Arteries from CABG patients showed increased vasoconstriction upon administration of the selective ETB receptor agonist sarafotoxin S6c, compared to healthy controls (P < 0.05). No such difference was found for the ETA receptors. AT1 and, to a lesser extent, AT2 receptor immunostaining was seen in the vascular smooth muscle cells. The level of AT1 receptor expression was higher in both the angina pectoris (128% +/- 25%; P < 0.05) and in the CABG patients (203% +/- 41%; P < 0.05), as compared to the healthy controls (100% +/- 25%). The increased AT1 receptor expression was confirmed by Western blotting. Myograph experiment did however not show any change in vasoconstriction to angiotensin II in CABG patients compared to healthy controls (P = n.s).
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 63 65 63 65 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 71 73 71 73 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
The results demonstrate, for the first time, upregulation of ETB and AT1 receptors in vascular smooth muscle cells in ischemic heart disease. These receptors may play a role in the pathophysiology of ischemic heart disease and could provide important targets for pharmaceutical interventions.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 142 143 142 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 294 295 294 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 296 297 296 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 589 590 589 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 741 742 741 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 768 769 768 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 792 793 792 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 546 554 <span type="species:ncbi:9606">patients</span>
The renin-angiotensin and the endothelin systems are essential in vascular homeostasis and may become maladaptive in cardiovascular diseases [1]. Angiotensin II and endothelin-1 are formed in the endothelium and induce potent vasoconstriction and proliferation of vascular smooth muscle cells [2,3]. The continuous production of endothelin-1 and angiotensin II in the endothelium is important for the control of vessel tone and changes in the endothelin- and renin-angiotensin-systems can give rise to dysfunctional vessels such as those seen in patients with cardiovascular risk factors [4]. Endothelin-1 and angiotensin II have therefore been suggested to play a role in the development if cardiovascular diseases, including hypertension [5], chronic heart failure [6] and atherosclerosis [7].
###end p 11
###begin p 12
###xml 109 110 109 110 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A</sub>
###xml 126 127 126 127 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 177 179 177 179 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A </sub>
###xml 301 303 301 303 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 434 435 434 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 440 442 440 442 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 585 586 585 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 618 620 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
Endothelin-1 mediates its effects through two distinct G-protein coupled receptors; the endothelin type A (ETA) and type B (ETB) receptors. During physiologic conditions, the ETA receptor is the dominant receptor subtype expressed in vascular smooth muscle cells and mediates contraction, while the ETB receptor is primarily located on endothelial cells and mediates vasodilatation via the release of nitric oxide and prostaglandins [8]. ETB receptors on vascular smooth muscle cells have however been observed to be upregulated during pathological conditions such as atherosclerosis [9] and congestive heart failure [10]. Endothelin receptors on vascular smooth muscle cells are both mitogenic, leading to atherosclerosis and can induce strong vasoconstriction, resulting in elevated vascular tone that contributes to the development of ischemic cardiovascular disease.
###end p 12
###begin p 13
###xml 60 62 60 62 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 68 70 68 70 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 235 237 235 237 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 339 341 339 341 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 469 471 469 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 476 478 476 478 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 809 811 809 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 53 56 <span type="species:ncbi:9606">man</span>
Two angiotensin II receptors have been identified in man, AT1 and AT2 receptors, which are members of the G-protein coupled seven-transmembrane domain receptor family. The vascular effects of angiotensin II are primarily mediated by AT1 receptors located on smooth muscle cells which induce vasoconstriction and mitogenesis. Conversely, AT2 receptors are located on endothelial cells and are known to induce vasodilatation, inhibit cell growth and stimulate apoptosis [11]. AT2 receptors have been shown, although to a lesser extent, in vascular smooth muscle cells. Angiotensin II acts, apart from being a potent vasoconstrictor also as a growth factor that regulates cell growth, differentiation and fibrosis, as well as being implicated in the pathology of heart failure, hypertension and atherosclerosis [11].
###end p 13
###begin p 14
###xml 222 231 222 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 822 824 822 824 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A </sub>
###xml 830 831 830 831 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 851 853 851 853 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 859 861 859 861 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 964 973 964 973 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 73 78 <span type="species:ncbi:9606">human</span>
###xml 292 300 <span type="species:ncbi:9606">patients</span>
###xml 544 552 <span type="species:ncbi:9606">patients</span>
###xml 554 562 <span type="species:ncbi:9606">Patients</span>
###xml 627 635 <span type="species:ncbi:9606">patients</span>
In vivo studies on the effects of endothelin-1 and angiotensin II in the human peripheral vasculature have previously mainly been performed using a forearm blood flow model. To the best of our knowledge, this is the first in vitro study using peripheral vascular tissue samples isolated from patients with different degrees of cardiovascular disease. The peripheral vasculature is contributing significantly to total peripheral resistance leading to our use of small peripheral arteries and arterioles, obtained from the subcutaneous tissue in patients. Patients with angina pectoris without established myocardial infarction, patients undergoing coronary artery bypass graft (CABG) surgery because of ischemic heart disease and cardiovascular healthy controls, were included in the study. The expressions of endothelin ETA and ETB, and angiotensin AT1 and AT2 receptors in vascular smooth muscle cells were studied by using immunohistochemistry, Western blot and in vitro pharmacology.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
Ethics
###end title 16
###begin p 17
The project was approved by the Ethics Committee of Lund University in Sweden (LU Dnr: 308/2004) and conforms to the principles outlined in the Declaration of Helsinki. Each individual provided written consent to the procedure.
###end p 17
###begin title 18
Study groups
###end title 18
###begin p 19
###xml 26 34 <span type="species:ncbi:9606">patients</span>
Three different groups of patients were included in the immunohistochemistry part of the study.
###end p 19
###begin p 20
1. Cardiovascular healthy controls (controls). This group consisted of ten healthy volunteers without previous history of chest pain, cardiovascular disease or prior cardiac medications. Blood samples for laboratory analysis were taken prior to the biopsy.
###end p 20
###begin p 21
###xml 11 19 <span type="species:ncbi:9606">patients</span>
###xml 84 92 <span type="species:ncbi:9606">patients</span>
###xml 122 130 <span type="species:ncbi:9606">patients</span>
###xml 327 335 <span type="species:ncbi:9606">patients</span>
2. Fifteen patients with angina pectoris without established myocardial infarction (patients with angina pectoris). These patients were admitted to the medical emergency unit with angina pectoris without signs of prior or ongoing myocardial infarction as measured by electrocardiogram and biomarkers for myocardial injury. The patients had no history of heart failure. Blood samples for laboratory analysis were taken at the telemetry unit after the chest pain had resolved.
###end p 21
###begin p 22
###xml 3 11 <span type="species:ncbi:9606">Patients</span>
###xml 83 91 <span type="species:ncbi:9606">patients</span>
###xml 233 241 <span type="species:ncbi:9606">patients</span>
3. Patients undergoing coronary artery bypass graft surgery (CABG) (n = 10). These patients underwent elective CABG because of stabile ischemic heart disease confirmed by angiography revealing coronary disease in three arteries. The patients had no prior known myocardial infarction but showed different degrees of heart failure secondary to their heart vessel disorder. Blood samples for laboratory analysis were taken the day before the surgical intervention.
###end p 22
###begin p 23
###xml 60 61 60 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 4 11 <span type="species:ncbi:9606">patient</span>
The patient background characteristics are defined in Table 1.
###end p 23
###begin p 24
Physical and Biochemical Characteristics in the Study Subjects
###end p 24
###begin p 25
Values are expressed as mean +/- SD. Statistical analysis was performed using ANOVA with Dunnet's post-test for multiple comparisons. Significance was defined as P < 0.05 (*). Abbreviations are: CABG, coronary artery bypass graft surgery; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol; NYHA, New York Heart Association Functional Classification; NT-proBNP, N-terminal pro B-type natriuretic peptide; ARB, angiotensin receptor blockers; ACEI, angiotensin converting enzyme inhibitors and BMI, body mass index.
###end p 25
###begin title 26
Tissue collection
###end title 26
###begin p 27
###xml 354 355 354 355 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 94 101 <span type="species:ncbi:9606">patient</span>
###xml 213 221 <span type="species:ncbi:9606">patients</span>
A biopsy was taken from the subcutaneous tissue of the abdomen. For the control group and the patient with angina pectoris, this was done during local anaesthesia (2 ml, 1% Xylocain; AstraZeneca, Sweden). For the patients undergoing CABG surgery the biopsy was taken under general anaesthesia during the initiation of surgery. A subcutaneous tissue (1 cm3), containing small arteries, was removed from the abdomen. The tissue was frozen in ice-cold isopentane and stored at -80degreesC.
###end p 27
###begin title 28
Immunohistochemistry
###end title 28
###begin p 29
###xml 67 69 61 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#956;</italic>
###xml 271 273 264 266 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 319 321 312 314 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A </sub>
###xml 394 396 387 389 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 468 470 461 463 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 251 257 <span type="species:ncbi:9986">rabbit</span>
###xml 263 268 <span type="species:ncbi:9606">human</span>
###xml 301 305 <span type="species:ncbi:9925">goat</span>
###xml 311 316 <span type="species:ncbi:9606">human</span>
###xml 374 380 <span type="species:ncbi:9986">rabbit</span>
###xml 386 391 <span type="species:ncbi:9606">human</span>
###xml 448 454 <span type="species:ncbi:9986">rabbit</span>
###xml 460 465 <span type="species:ncbi:9606">human</span>
###xml 522 527 <span type="species:ncbi:10090">mouse</span>
###xml 533 538 <span type="species:ncbi:9606">human</span>
###xml 577 582 <span type="species:ncbi:10090">mouse</span>
###xml 588 593 <span type="species:ncbi:9606">human</span>
###xml 682 686 <span type="species:ncbi:9913">calf</span>
###xml 862 868 <span type="species:ncbi:9793">donkey</span>
###xml 874 880 <span type="species:ncbi:9986">rabbit</span>
###xml 951 957 <span type="species:ncbi:9793">donkey</span>
###xml 963 967 <span type="species:ncbi:9925">goat</span>
###xml 1041 1047 <span type="species:ncbi:9793">donkey</span>
###xml 1053 1058 <span type="species:ncbi:10090">mouse</span>
The biopsies were stored at -80degreesC prior to sectioning into 8-mum-thick slices in a calibrated Microm HM500M cryostat (Microm). The sections were fixed and rehydrated in phosphate-buffered saline (PBS). The sections were incubated overnight with rabbit anti-human ETB (16207, IBL) diluted 1:400, goat anti-human ETA (sc-21194, Santa Cruz Biotechnologies) diluted 1:50, rabbit anti-human AT1 (sc-1173, Santa Cruz Biotechnologies) diluted 1:50, rabbit anti-human AT2 (sc-9040, Santa Cruz Biotechnologies) diluted 1:50, mouse anti-human CD-31 (M0823, DAKO) diluted 1:100 and mouse anti-human alpha-actin (M0851, DAKO) diluted 1:1000. All dilutions were done in PBS with 10% fetal calf serum. Antibodies to alpha-actin were used to localize smooth muscle cells and antibodies to CD-31 were used to localize endothelial cells. The secondary antibodies used were donkey anti-rabbit Cytrade mark3 conjugated (711-165-152, Jackson ImmunoResearch) 1:100, donkey anti-goat Cytrade mark3 conjugated (705-165-003, Jackson ImmunoResearch) 1:100 and donkey anti-mouse Texas Red conjugated (715-076-150, Jackson ImmunoResearch) 1:200 in PBS. Only secondary antibodies were used as control. The antibodies were directed against a part of the respective receptor protein; this amino acid sequence was used as a control to block the antigenic site. The data from both immunocytochemistry and Western blot are given at the respective company's home page.
###end p 29
###begin title 30
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
In vitro pharmacology
###end title 30
###begin p 31
###xml 262 263 262 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 638 640 638 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 779 781 773 775 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 808 810 802 804 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 838 839 832 833 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 841 843 835 837 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4 </sub>
###xml 942 944 936 938 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1296 1298 1290 1292 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 1363 1366 1357 1360 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-11</sup>
###xml 1369 1372 1363 1366 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 1435 1439 1429 1433 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-14 </sup>
###xml 1444 1447 1438 1441 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-7 </sup>
###xml 1497 1501 1491 1495 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-12 </sup>
###xml 1506 1509 1500 1503 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 1594 1596 1588 1590 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1629 1634 1623 1628 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-5.5 </sup>
###xml 1761 1764 1755 1758 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-11</sup>
###xml 1767 1770 1761 1764 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6 </sup>
###xml 1792 1793 1786 1787 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B</sub>
###xml 1822 1824 1816 1818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1886 1888 1880 1882 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A </sub>
###xml 1923 1928 1917 1922 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 1931 1933 1925 1927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 82 90 <span type="species:ncbi:9606">patients</span>
The resistance arteries were removed from the abdomen from cardiovascular healthy patients undergoing abdominal reduction surgery (n = 5) or during CABG surgery (n = 5). The subjects had the same clinical characteristics as those for immunohistochemistry (Table 1). Vessels were placed in saline buffer on ice, transported to the laboratory and subsequently analyzed for their contractile properties in a myograph recording their isometric tension. The vessels were cut into 1-mm-long cylindrical segments and mounted on two L-shaped metal prongs, unilaterally a force displacement transducer continuously recorded the isometric tension [12]. Mounted vessel segments were immersed in vessel baths at 37degreesC containing a bicarbonate based buffer solution; NaCl (119 mM), NaHCO3 (15 mM), KCl (4.6 mM), CaCl2 (1.5 mM), MgCl (1.2 mM), NaH2PO4 (1.2 mM), and glucose (5.5 mM). The buffer was continuously aerated with oxygen enriched with 5% CO2 resulting in pH 7.4. Initially vessels were stretched to a resting tone of 2 mN and was then allowed to stabilize at this tension for 1 h. Contractile capacity of each arterial vessel segment was controlled by exposure to a potassium rich (63.5 mM) buffer solution. Concentration-response curves were obtained by cumulative application of endothelin ETB receptor agonist, sarafotoxin 6c at increasing concentrations (10-11-10-6 mM), ET-1 (AnaSpec, San Jose, CA) in the concentration range 10-14 to 10-7 M and angiotensin II in the concentration range 10-12 to 10-6 M. Before the application of angiotensin II, the arteries were pretreated with the AT2 receptor antagonist PD-123319 (10-5.5 M) for 30 min. After washout, the vessels returned to baseline and endothelin-1 was then added at increasing concentrations (10-11-10-6 mM) when endothelin ETBreceptors were desensitized [13] facilitating endothelin-1 to act solely on the endothelin ETA receptors. For details see Nilsson et al. [14].
###end p 31
###begin p 32
The drugs used, endothelin-1 (ET-1), sarafotoxin 6c (S6c), angiotensin II and PD-123319 were purchased from Sigma Chemical Co (St. Louis, MO). They were dissolved in 0.9% NaCl with 10% albumin.
###end p 32
###begin title 33
Western Blot Analysis
###end title 33
###begin p 34
###xml 1088 1090 1075 1077 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 1153 1155 1140 1142 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 55 63 <span type="species:ncbi:9606">patients</span>
###xml 1075 1080 <span type="species:ncbi:9940">sheep</span>
###xml 1139 1145 <span type="species:ncbi:9986">rabbit</span>
###xml 1187 1193 <span type="species:ncbi:9986">rabbit</span>
###xml 1366 1371 <span type="species:ncbi:9940">sheep</span>
###xml 1397 1403 <span type="species:ncbi:9986">rabbit</span>
###xml 1453 1464 <span type="species:ncbi:3704">horseradish</span>
Human vessels (4 from healthy donators and 5 from CABG patients) were frozen in liquid nitrogen and homogenized in cell extract denaturing buffer (BioSource, USA) with addition of a protease inhibitor cocktail (Sigma, USA). Whole cell lysates were sonicated for 2 min on ice, centrifuged at 15,000 x g at 4degreesC for 30 min, and the supernatants were collected as protein samples. The protein concentrations were determined using the protein assay reagents (Bio-Rad, Hercules, CA, USA) and stored at -80degreesC until immunoblotting assay. The protein homogenates were diluted 7:2:1(v/v) with 5x LDS Sample Buffer and 10x DTT Reducer (PAGEgel, Inc. San Diego, CA, USA). A total of 40-50 mug of protein was boiled for 5 min and separated by 4-12% SDS Ready Gels (PAGEgel, Inc., USA) for 120 min at 100 v, and transferred electrophoretically to nitrocellulose membranes (Bio-Rad) at 100 v for 60 min. The membrane was then blocked for 1 h at room temperature with phosphate buffered saline (PBS) containing 0.1% Tween-20 (Sigma) and 5% non-fat dried milk, and incubated with sheep anti-ETB (Enzo Life Sciences Inc., Farmingdale, NY, USA), rabbit anti-AT1 (Abcam plc., Cambridge, UK), or rabbit anti-beta-actin (Cell Signaling Technology, Inc., Boston, MA, USA) polyclonal primary antibodies diluted 1:200-500 overnight at 4degreesC, followed by incubation with anti-sheep (Abcam plc., UK) or anti-rabbit (Amersham Biosciences, Piscataway, NJ, USA) IgG, horseradish peroxidase (HRP)-conjugated secondary antibodies diluted 1: 5000 for 1 h at room temperature. The probed proteins were developed by LumiSensor Chemiluminescent HRP Substrate kit (GenScript Corp., Piscataway, NJ, USA). To detect multiple signals using a single membrane, the membrane was incubated for 5-15 min at room temperature with restored plus Western blot stripping buffer (Pierce Biotechnology, Inc., Rockford, IL. USA). The membranes were visualized using a Fujifilm LAS-1000 Luminiscent Image Analyzer (Stamford, CT, USA.). The quantification of band intensity was analyzed with Image Gauge Ver. 4.0 (Fuji Photo Film Co., LTD., Japan). The expression of target proteins were presented as a relative extent to the level of beta-actin and normalized to the percentage of control.
###end p 34
###begin title 35
Calculations and statistics
###end title 35
###begin title 36
Immunohistochemistry
###end title 36
###begin p 37
###xml 54 62 <span type="species:ncbi:9606">patients</span>
###xml 88 96 <span type="species:ncbi:9606">patients</span>
###xml 806 814 <span type="species:ncbi:9606">patients</span>
###xml 917 925 <span type="species:ncbi:9606">patients</span>
The experiments were performed using arteries from 15 patients with angina pectoris, 10 patients undergoing CABG surgery and 10 healthy controls. The samples were examined in a fluorescence microscope (Olympus optical Co, LTD, Bx60F5) and the absolute fluorescence intensity was measured with ImageJ . Mean fluorescence values in the area selected were obtained in three sections and at four different regions, and the mean values were calculated. Statistical analysis was performed using ANOVA with Bonferroni's or Dunnet's post-test for multiple comparisons. Significance was defined as P < 0.05 (*). The data are given in the text as percentage difference relative to the mean fluorescence seen in the control. The results are presented as mean values +/- standard deviation (SD) and N equals number of patients. Values are presented as percent fluorescence in the angina and CABG groups compared with the control patients group, where the control group is set to 100%.
###end p 37
###begin title 38
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
In vitro pharmacology
###end title 38
###begin p 39
###xml 115 119 115 119 <sub xmlns:xlink="http://www.w3.org/1999/xlink">max </sub>
###xml 204 206 204 206 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 497 499 497 499 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 620 621 618 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
The contractile reaction in each segment is expressed as percentage of the 63.5 mM potassium induced contraction. Emax value represents the maximum contractile response elicited by an agonist, and the pEC50, the negative logarithm of the drug concentration that elicited half the maximum response. Linear regression analysis was applied using values obtained from above and below half-maximum response for calculating the negative logarithm of the concentrations that produced 50% contraction (pEC50). Data are presented as mean +/- standard error of the mean (S.E.M). Statistical analyses was performed using Student's t-test.
###end p 39
###begin title 40
Western Blot
###end title 40
###begin p 41
###xml 82 83 82 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
Comparisons between two groups were performed using two-tailed unpaired Student's t-test. A p-value less than 0.05 were considered to be significant. Results were presented as mean +/- S.E.M.
###end p 41
###begin title 42
Results
###end title 42
###begin title 43
Endothelin receptor expression
###end title 43
###begin p 44
###xml 68 70 68 70 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A </sub>
###xml 97 99 97 99 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 147 149 147 149 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 357 358 353 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 363 364 359 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 396 398 392 394 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 587 589 583 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 608 610 604 606 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A </sub>
###xml 727 729 723 725 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 192 200 <span type="species:ncbi:9606">patients</span>
###xml 263 271 <span type="species:ncbi:9606">patients</span>
###xml 487 495 <span type="species:ncbi:9606">patients</span>
###xml 550 557 <span type="species:ncbi:9606">patient</span>
In healthy controls, the vascular smooth muscle cells stained for ETA and, to a lesser extent, ETB receptors. The immunostaining intensities for ETB receptors were higher in arteries from the patients undergoing CABG surgery (250% +/- 23%; P < 0.05) and from the patients with angina pectoris (199% +/- 6%; P < 0.05), than from the healthy controls (Figure 1 and 2). Furthermore, the levels of ETB receptor expression were higher in the smooth muscle cell layer in the arteries from the patients undergoing CABG surgery than in the arteries from the patient with angina pectoris (Figure 1B). The levels of ETA receptor expression, in the smooth muscle cells, were similar in all three groups (P = n.s.). In endothelial cells ETB receptor immunostaining was primarily observed, however, it was not different among the groups.
###end p 44
###begin p 45
###xml 2 4 2 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A </sub>
###xml 14 16 14 16 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 0 111 0 111 <bold xmlns:xlink="http://www.w3.org/1999/xlink">ET<sub>A </sub>(A) and ET<sub>B </sub>(B) receptor protein expression assessed by immunohistochemistry in human subcutaneous arteries</bold>
###xml 84 89 <span type="species:ncbi:9606">human</span>
###xml 140 148 <span type="species:ncbi:9606">patients</span>
###xml 248 256 <span type="species:ncbi:9606">patients</span>
ETA (A) and ETB (B) receptor protein expression assessed by immunohistochemistry in human subcutaneous arteries. Vessles were obtained from patients undergoing coronary artery bypass graft (CABG) surgery because of ischemic heart disease (n = 10), patients with angina pectoris without established myocardial infarction (n = 15) and cardiovascular healthy controls (n = 10). Values are expressed as mean +/- SD. Statistical analysis was performed using ANOVA with Dunnet's post-test for multiple comparisons. Significance was defined as P < 0.05 (*).
###end p 45
###begin p 46
###xml 78 80 78 80 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 86 88 86 88 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 0 128 0 128 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Representative examples showing immunofluorescence staining experiments for ET<sub>B </sub>and AT<sub>1 </sub>receptors in human subcutaneous arteries</bold>
###xml 442 444 442 444 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 450 452 450 452 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 101 106 <span type="species:ncbi:9606">human</span>
###xml 157 165 <span type="species:ncbi:9606">patients</span>
###xml 265 273 <span type="species:ncbi:9606">patients</span>
###xml 517 525 <span type="species:ncbi:9606">patients</span>
Representative examples showing immunofluorescence staining experiments for ETB and AT1 receptors in human subcutaneous arteries. Vessels were obtained from patients undergoing coronary artery bypass graft (CABG) surgery because of ischemic heart disease (n = 10), patients with angina pectoris without established myocardial infarction (n = 15) and cardiovascular healthy controls (n = 10). Note that the immunostaining intensity for both ETB and AT1 receptors, indicated with arrows, is higher in the arteries from patients with ischemic heart disease then from healthy controls. Magnification x 400 for all photomicrographs.
###end p 46
###begin p 47
###xml 19 21 19 21 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 217 218 217 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 314 316 314 316 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 423 424 421 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 176 184 <span type="species:ncbi:9606">patients</span>
###xml 256 264 <span type="species:ncbi:9606">patients</span>
Western blot for ETB receptors detected a single band with the approximate molecular weight of 53 kDa in the artery homogenates from all samples including healthy controls and patients undergoing CABG surgery (Figure 3). Densitometric analysis showed that patients undergoing CABG surgery had a mean increase of ETB receptors expression (133 +/- 8%; P < 0.05), which was significantly more than in healthy controls (Figure 3)
###end p 47
###begin p 48
###xml 2 4 2 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 14 16 14 16 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 0 107 0 107 <bold xmlns:xlink="http://www.w3.org/1999/xlink">ET<sub>B </sub>(A) and AT<sub>1 </sub>(B) receptor protein expression in human subcutaneous arteries, examined using Western blot</bold>
###xml 392 393 390 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 51 56 <span type="species:ncbi:9606">human</span>
###xml 139 147 <span type="species:ncbi:9606">patients</span>
###xml 189 197 <span type="species:ncbi:9606">patients</span>
ETB (A) and AT1 (B) receptor protein expression in human subcutaneous arteries, examined using Western blot. Arteries from healthy control patients (n = 4) were compared with arteries from patients undergoing CABG surgery (n = 5). The results are shown as mean values +/- S.E.M above the actual Western blot data with beta-actin as control. Statistical analyses was performed using Student's t-test, where P < 0.05 (*) was considered significant.
###end p 48
###begin title 49
Angiotensin II receptor expression
###end title 49
###begin p 50
###xml 47 49 47 49 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 80 82 80 82 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 109 111 109 111 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 286 287 282 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 292 293 288 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 325 327 321 323 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 506 508 502 504 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 590 592 586 588 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 764 766 760 762 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 962 963 958 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 1059 1061 1055 1057 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1167 1168 1161 1162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 212 220 <span type="species:ncbi:9606">patients</span>
###xml 408 416 <span type="species:ncbi:9606">patients</span>
###xml 463 470 <span type="species:ncbi:9606">patient</span>
###xml 921 929 <span type="species:ncbi:9606">patients</span>
###xml 1001 1009 <span type="species:ncbi:9606">patients</span>
The vascular smooth muscle cells stained for AT1 and, to a lesser extent, for AT2 receptors. The levels of AT1 receptor expression were higher in both the angina pectoris (128% +/- 25%; P < 0.05) and in the CABG patients (203% +/- 41%; P < 0.05), than from the healthy controls (Figure 2 and 4). In addition, the levels of AT1 receptor expression were higher in the smooth muscle cell layer in arteries from patients undergoing CABG surgery than in arteries from patient with angina pectoris (P < 0.05). AT2 receptor expression was similar in all three groups. In endothelial cells, only AT2 receptor immunostaining was observed. Since the numbers of cells in the endothelial cell layer are limited, no comparisons were made between the groups. Western blot for AT1 receptors detected a single band with the approximate molecular weight of 41 kDa in the artery homogenates from all samples including healthy controls and patients undergoing CABG surgery (Figure 3). Densitometric analysis showed that patients undergoing CABG surgery had a mean increase of AT1 receptors expression (137 +/- 9%; P < 0.05) which was significantly more than in healthy controls (Figure 3).
###end p 50
###begin p 51
###xml 2 4 2 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 14 16 14 16 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 0 111 0 111 <bold xmlns:xlink="http://www.w3.org/1999/xlink">AT<sub>1 </sub>(A) and AT<sub>2 </sub>(B) receptor protein expression assessed by immunohistochemistry in human subcutaneous arteries</bold>
###xml 84 89 <span type="species:ncbi:9606">human</span>
###xml 140 148 <span type="species:ncbi:9606">patients</span>
###xml 248 256 <span type="species:ncbi:9606">patients</span>
AT1 (A) and AT2 (B) receptor protein expression assessed by immunohistochemistry in human subcutaneous arteries. Vessels were obtained from patients undergoing coronary artery bypass graft (CABG) surgery because of ischemic heart disease (n = 10), patients with angina pectoris without established myocardial infarction (n = 15) and cardiovascular healthy controls (n = 10). Values are expressed as mean +/- SD. Statistical analysis was performed using ANOVA with Dunnet's post-test for multiple comparisons. Significance was defined as P < 0.05 (*).
###end p 51
###begin title 52
Actin and CD-31 immunostaining
###end title 52
###begin p 53
###xml 71 73 71 73 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 79 81 79 81 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 205 206 205 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 443 444 443 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
Double immunostaining showed co localization between on one hand the AT1 and ETB receptors and on the other hand smooth muscle cell alpha-actin in resistance arteries. As shown in the illustration (Figure 5) there was clear co localization between the two receptor subtypes and alpha-actin both in control and in CABG subjects. CD-31 was used to stain endothelial cells; we observed weak co localization between both receptor and CD31 (Figure 5).
###end p 53
###begin p 54
###xml 25 27 25 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 33 35 33 35 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 0 98 0 98 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Co localization of the AT<sub>1 </sub>and ET<sub>B </sub>receptors to vascular smooth muscle cells and endothelial cells</bold>
###xml 144 146 144 146 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 152 154 152 154 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 252 254 252 254 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 255 260 255 260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 262 264 262 264 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A1</bold>
###xml 266 271 266 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrow</italic>
###xml 298 301 298 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 303 306 303 306 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A2 </bold>
###xml 306 311 306 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrow</italic>
###xml 314 317 314 317 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A3 </bold>
###xml 325 328 325 328 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A1 </bold>
###xml 332 334 332 334 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A2</bold>
###xml 353 355 353 355 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 356 361 356 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 363 365 363 365 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B1</bold>
###xml 367 372 367 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrow</italic>
###xml 399 402 399 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 404 406 404 406 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B2</bold>
###xml 408 413 408 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrow</italic>
###xml 416 420 416 420 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B3 (</bold>
###xml 455 457 455 457 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 458 463 458 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 465 467 465 467 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C1</bold>
###xml 469 474 469 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrow</italic>
###xml 487 490 487 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 492 494 492 494 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C2</bold>
###xml 495 500 495 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrow</italic>
###xml 503 506 503 506 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C3 </bold>
###xml 514 516 514 516 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C1</bold>
###xml 517 519 517 519 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C2</bold>
###xml 538 540 538 540 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 541 546 541 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 548 550 548 550 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D1</bold>
###xml 552 557 552 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrow</italic>
###xml 570 573 570 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 575 577 575 577 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D2</bold>
###xml 579 584 579 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrow</italic>
###xml 587 591 587 591 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D3 (</bold>
###xml 598 601 598 601 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D1 </bold>
###xml 605 607 605 607 <bold xmlns:xlink="http://www.w3.org/1999/xlink">D2</bold>
###xml 226 234 <span type="species:ncbi:9606">patients</span>
Co localization of the AT1 and ETB receptors to vascular smooth muscle cells and endothelial cells. Immunostaining and co localization of the AT1 and ETB receptors to alpha-SMC and endothelin in resistance arteries of control patients. Antibodies to AT1 (green, A1, arrow) and smooth muscle actin (red, A2 arrow), A3 (merged A1 and A2). Antibodies to ETB (green, B1, arrow) and smooth muscle actin (red, B2, arrow), B3 (merged B1 and B2). Antibodies to AT1 (green, C1, arrow) and CD-31 (red, C2,arrow), C3 (merged C1+C2). Antibodies to ETB (green, D1, arrow) and CD-31 (red, D2, arrow), D3 (merged D1 and D2). Magnification x 400 for all photomicrographs.
###end p 54
###begin title 55
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
In vitro Pharmacology
###end title 55
###begin p 56
###xml 16 18 16 18 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 59 61 59 61 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 232 234 232 234 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A </sub>
###xml 539 541 539 541 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 583 585 583 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6A</xref>
###xml 764 766 764 766 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A </sub>
###xml 816 818 816 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6B</xref>
###xml 966 968 966 968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6C</xref>
###xml 997 1002 997 1002 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(124 </italic>
###xml 371 379 <span type="species:ncbi:9606">patients</span>
###xml 667 675 <span type="species:ncbi:9606">patients</span>
The selective ETB receptor agonist S6c was used to study ETB mediated contraction. Afterwards ET-1 induced vasoconstriction was studied when endothelin B receptors were desensitized by the previous application of S6c leaving only ETA receptors available for a contractile response. Sarafotoxin 6c induced no vasoconstriction in healthy control vessels. On the other hand patients undergoing CABG showed a fairly strong and significant contractile response to the cumulative application of S6c (P < 0.05 n = 5) suggesting upregulation of ETB receptors at the functional level (Figure 6A). Endothelin-1 induced a potent vasoconstriction in both healthy controls and in patients undergoing CABG surgery (P = ns) indicating that there were no obvious changes in the ETA receptor responses between the two groups (Figure 6B). Angiotensin II induced concentration-dependent contractions of the arteries were strong but there were no differences between the groups (Figure 6C). The potassium rich buffer (124 mM) resulted in strong persistent contractions of the resistance arteries with no differences between the groups (data not shown).
###end p 56
###begin p 57
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>In vitro </italic>pharmacology</bold>
###xml 367 368 365 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 192 200 <span type="species:ncbi:9606">patients</span>
In vitro pharmacology. Concentration-response curves to increasing concentrations of (A) sarafotoxin 6c, (B) endothelin-1, and (C) angiotensin II in arteries from healthy controls (n = 5) and patients undergoing CABG surgery (n = 5). The results are shown as mean values +/- S.E.M of five experiments in each group. Statistical analyses was performed using Student's t-test, where P < 0.05 (*) was considered significant.
###end p 57
###begin title 58
Demographics
###end title 58
###begin p 59
###xml 64 65 64 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 153 160 <span type="species:ncbi:9606">patient</span>
The patients' background characteristics are described in Table 1. Taken together, the systolic blood pressure and C reactive protein were higher in the patient with ischemic heart disease (both CABG and angina pectoris). The plasma levels of N-terminal pro B-type natriuretic peptide (NT-proBNP) were higher in the CABG and the angina pectoris groups than in the cardiovascular healthy controls.
###end p 59
###begin title 60
Discussion
###end title 60
###begin title 61
Endothelin receptor expression and function
###end title 61
###begin p 62
###xml 45 47 45 47 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 209 211 209 211 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 135 143 <span type="species:ncbi:9606">patients</span>
###xml 264 272 <span type="species:ncbi:9606">patients</span>
Our results clearly show that the level of ETB receptor expression is higher in the vascular smooth muscle cell layer of arteries from patients with angina pectoris than from healthy controls. The levels of ETB receptor expression are even higher in arteries from patients undergoing CABG surgery. We hypothesize that there is a progressive upregulation of this receptor subtype that may correlate with the degree of cardiovascular disease.
###end p 62
###begin p 63
###xml 14 16 14 16 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 190 191 190 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 192 194 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 195 197 195 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 343 345 343 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 435 437 435 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 610 612 610 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 613 615 613 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 769 771 769 771 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 816 818 816 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 847 849 847 849 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 978 980 978 980 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 1089 1091 1089 1091 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 118 123 <span type="species:ncbi:9606">human</span>
###xml 238 246 <span type="species:ncbi:9606">patients</span>
###xml 401 409 <span type="species:ncbi:9606">patients</span>
###xml 636 644 <span type="species:ncbi:9606">patients</span>
Upregulated ETB receptors on vascular smooth muscle cells have previously been shown in diabetes, hypertension and in human atherosclerotic coronary arteries and in atherosclerotic plaques [9,15,16]. Plasma levels of ET-1 are elevated in patients with ischemic heart disease and in heart failure; it has been suggested as a prognostic marker [17]. The circulating ET-1 levels are further increased in patients undergoing CABG surgery [18]. This increased activity in the endothelin system may contribute to smooth muscle cell proliferation, vasoconstriction and decreased perfusion in atherosclerotic disease [19-21]. Furthermore, CABG patients had significantly increased pro-BNP levels indicating some degree of heart failure, a condition associated with increased ETB receptor mediated systemic vasoconstriction [22]. The elevated endothelin ETB contraction in the present study, also verified by Western blot, indicates that the increased levels of contractile endothelin ETB receptors on the vascular smooth muscle cells could play an important role in ischemic heart disease since ETB receptor activation in healthy controls did not induce any contractions at all.
###end p 63
###begin title 64
###xml 44 46 44 46 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
Mechanisms underlying the upregulation of ETB receptors
###end title 64
###begin p 65
###xml 41 43 41 43 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 126 128 126 128 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 252 254 252 254 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 353 355 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 516 518 516 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 519 521 519 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 712 714 705 707 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 725 727 718 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 896 898 889 891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 365 370 <span type="species:ncbi:9606">human</span>
###xml 748 756 <span type="species:ncbi:9606">patients</span>
The mechanism underlying the increased ETB receptor expression is not known, but could depend on increased transcription of ETB receptor mRNA triggered by some of the many humeral factors that are increased in ischemic heart disease. Upregulation of ETB receptors is known to rely on increased transcription and subsequent translation of receptor mRNA [23]. In the human genome, the 5'-flanking region of the genes encoding the endothelin receptors contain several regulatory elements, like GATA-motifs and E-boxes [24,25]. This indicates that the genes might be activated by for example inflammatory components. Indeed, the presence of interleukin-1beta and TNF-alpha may enhance the upregulation of vascular ETB receptors [26]. In agreement, the patients with ischemic heart disease had higher plasma levels of C reactive protein. Atherosclerosis is known to induce a proinflammatory response [27] and this may in part regulate endothelin receptor expression.
###end p 65
###begin title 66
Angiotensin II receptor expression
###end title 66
###begin p 67
###xml 38 40 38 40 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 428 430 428 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 447 449 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 461 463 461 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 488 490 488 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 511 513 511 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 746 748 746 748 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 868 870 868 870 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1120 1122 1120 1122 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1256 1258 1256 1258 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1328 1330 1328 1330 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1388 1390 1388 1390 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 102 110 <span type="species:ncbi:9606">patients</span>
###xml 281 289 <span type="species:ncbi:9606">patients</span>
###xml 1282 1290 <span type="species:ncbi:9606">patients</span>
In the present study, the levels of AT1 receptor expression were higher in subcutaneous arteries from patients with ischemic heart disease than in the healthy controls as verified by immunohistochemistry and Western blot. The levels of expression were even higher in arteries from patients undergoing CABG surgery. The plasma level of angiotensin II is known to be elevated in different heart conditions, such as heart failure [28], hypertension [29], hypoxia [30], hypercholesterolemia [31] and hyperglycemia [32]. We have found, herein, that this may be associated with enhanced expression of vascular angiotensin II receptors. Angiotensin II is a potent vasoconstrictor and mitogen of coronary artery smooth muscle cells. The stimulation of AT1 receptors results in progression of atherosclerotic lesions, inflammation and plaque rupture. Increased expression of AT1 receptors might make the vasculature prone to develop spasm and atherosclerotic plaques, and thus further increase peripheral vascular resistance and reduce lumen. However, we did not observe any enhanced contraction of angiotensin II mediated via AT1 receptors as a result of an increased expression in the myograph experiments. One explanation to this could be the increased use of AT1 receptor antagonists in patients undergoing CABG, thus blocking the AT1 receptors. It is important, however, not to forget that AT1 receptors apart from their contractile properties also possess other abilities such as regulating cell growth, differentiation and fibrosis which are important in the pathology of heart failure, hypertension and atherosclerosis.
###end p 67
###begin title 68
###xml 44 46 44 46 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
Mechanisms underlying the upregulation of AT1 receptors
###end title 68
###begin p 69
###xml 48 50 48 50 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 216 218 216 218 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 286 288 286 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 516 518 516 518 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 539 541 539 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 556 558 556 558 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 823 825 823 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 73 81 <span type="species:ncbi:9606">patients</span>
###xml 378 386 <span type="species:ncbi:9606">patients</span>
The mechanisms underlying the upregulation of AT1 receptor expression in patients with ischemic heart disease cannot be deduced from the present study. Inflammatory mediators, such as IL-1 and IL-6, may upregulate AT1 receptors and enhance angiotensin II stimulated vessel hypertrophy [33]. In the present study, the observed plasma levels of C reactive protein was elevated in patients with ischemic heart disease. It has previously been shown that high levels of C reactive protein correlate with high levels of AT1 receptor expression [34]. Increased AT1 receptor expression has therefore been associated with vascular inflammation. C reactive protein is known to independently predict risk for myocardial infarction, stroke, peripheral artery disease and sudden cardiac death even among apparently healthy individuals [35].
###end p 69
###begin title 70
Clinical perspective
###end title 70
###begin p 71
###xml 317 319 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 397 399 397 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 523 525 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 991 999 <span type="species:ncbi:9606">patients</span>
Both ET-1 and angiotensin II have strong impact on cardiovascular diseases as discussed above; herein we will discuss their involvements in other situations: CABG surgery is hampered by deleterious vasospasm in arterial grafts. It has been suggested that impaired vasomotor function may contribute to this vasospasm [36]. Plasma levels of ET-1 and angiotensin II are elevated during CABG surgery [18]. Both endothelin and angiotensin II receptors have been shown to mediate strong vasoconstrictor effects in bypass grafts [28]. Many measures have been undertaken to control the vessel tone during surgery, including dilating the vessels with potent vasodilators such as papaverine, sodium nitroprusside and nifedipine, or mechanically distending the vessels with saline. It might be important to consider endothelin and angiotensin II receptor antagonists for this indication especially since the present results show increased levels of endothelin and angiotensin II receptor expression in patients undergoing CABG surgery.
###end p 71
###begin p 72
###xml 66 68 66 68 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 521 523 521 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 659 661 659 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 843 845 843 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1005 1006 1005 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
Angiotensin converting enzyme inhibitors (ACEI) and angiotensin AT1 receptor antagonists are frequently being used to prevent the development of target organ damage in atherosclerotic disease and in hypertension [37]. Whether endothelin receptor antagonists will become part of the therapeutic armamentarium in ischemic heart disease remains unclear, and none of these agents is currently being developed for this indication. However, the mixed endothelin blocker Bosentan is used in treatment of pulmonary hypertension [38] and other non-selective ET receptor antagonists have been shown to inhibit the development of atherosclerosis in experimental models [39]. New endothelin antagonists devoid of side effects and perhaps specific for either of the receptor subtypes are discussed in treatment of vasospasm after subarachnoid haemorrhage [40], or alternative inhibitors of the endothelin converting enzymes that generate endothelin-1 may in the future become available to block the endothelin system [5].
###end p 72
###begin title 73
Limitations
###end title 73
###begin p 74
###xml 61 63 61 63 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 69 71 69 71 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 366 368 366 368 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 84 92 <span type="species:ncbi:9606">patients</span>
###xml 135 143 <span type="species:ncbi:9606">patients</span>
###xml 212 220 <span type="species:ncbi:9606">patients</span>
###xml 403 411 <span type="species:ncbi:9606">patients</span>
The present study has demonstrated increased expression of ETB and AT1 receptors in patients with ischemic heart disease. However, the patients have confounding factors. The systolic blood pressure was higher in patients with ischemic heart disease compared to the healthy controls. Furthermore, the prevalence of medication with statins, beta blockers, ACEI, and AT1 receptor antagonists was common in patients with ischemic heart disease while they were non-existing in our healthy controls. The effect of these confounding factors on the endothelin and angiotensin II receptor expression cannot be concluded from the present study.
###end p 74
###begin title 75
Conclusion
###end title 75
###begin p 76
###xml 93 95 93 95 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 101 103 101 103 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 190 192 190 192 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 198 200 198 200 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 367 369 367 369 <sub xmlns:xlink="http://www.w3.org/1999/xlink">A </sub>
###xml 374 376 374 376 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 429 431 429 431 <sub xmlns:xlink="http://www.w3.org/1999/xlink">B </sub>
###xml 437 439 437 439 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 37 45 <span type="species:ncbi:9606">patients</span>
###xml 286 294 <span type="species:ncbi:9606">patients</span>
The present study clearly shows that patients with ischemic heart disease have upregulated ETB and AT1 receptors in the smooth muscle cells of peripheral resistance arteries. The level of ETB and AT1 expression correlates with the degree of ischemic heart disease, being highest in the patients undergoing CABG surgery. There was no difference in the expression of ETA or AT2 receptors between the study groups. The changes in ETB and AT1 receptor expression may be signs of remodeling of the vasculature, which is characteristic of ongoing ischemic heart disease.
###end p 76
###begin title 77
Competing interests
###end title 77
###begin p 78
The authors declare that they have no competing interests.
###end p 78
###begin title 79
Authors' contributions
###end title 79
###begin p 80
###xml 155 162 <span type="species:ncbi:9606">patient</span>
ID planned and executed the immunofluorescence experiments, analyzed the data, preformed the surgical procedure and wrote the manuscript. MLE acquired the patient data, the biopsies and reviewed the manuscript. QC preformed the Western blot experiments and wrote the associated texts. MM participated in the writing of the manuscript. POK performed the thoracic surgical procedure, removed the vessels and reviewed the manuscript. LE conceived and planned the study, and carefully reviewed the data and assisted in writing of the manuscript.
###end p 80
###begin title 81
Pre-publication history
###end title 81
###begin p 82
The pre-publication history for this paper can be accessed here:
###end p 82
###begin p 83

###end p 83
###begin title 84
Acknowledgements
###end title 84
###begin p 85
Supported by Swedish Research Council (grant 5958) and the Heart and Lung Foundation.
###end p 85
###begin article-title 86
Vasopeptidase inhibitors: will they have a role in clinical practice?
###end article-title 86
###begin article-title 87
A novel potent vasoconstrictor peptide produced by vascular endothelial cells
###end article-title 87
###begin article-title 88
Activation of endothelial nitric oxide synthase by the angiotensin II type 1 receptor
###end article-title 88
###begin article-title 89
Atherogenic lipids, vascular dysfunction, and clinical signs of ischemic heart disease
###end article-title 89
###begin article-title 90
Vascular endothelin in hypertension
###end article-title 90
###begin article-title 91
Heart failure and endothelin receptor antagonists
###end article-title 91
###begin article-title 92
###xml 72 77 <span type="species:ncbi:9606">human</span>
Increased immunoreactivity of endothelin-1 and endothelin B receptor in human atherosclerotic lesions. A possible role in atherogenesis
###end article-title 92
###begin article-title 93
Pathophysiology of endothelin in the cardiovascular system
###end article-title 93
###begin article-title 94
###xml 59 64 <span type="species:ncbi:9606">human</span>
Up-regulation of endothelin-B receptors in atherosclerotic human coronary arteries
###end article-title 94
###begin article-title 95
Enhanced coronary vasoconstriction to endothelin-B-receptor activation in experimental congestive heart failure
###end article-title 95
###begin article-title 96
Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system
###end article-title 96
###begin article-title 97
###xml 25 28 <span type="species:ncbi:10116">rat</span>
Mechanical properties of rat cerebral arteries as studied by a sensitive device for recording of mechanical activity in isolated small blood vessels
###end article-title 97
###begin article-title 98
Functional role of endothelin ETA and ETB receptors in venous and arterial smooth muscle
###end article-title 98
###begin article-title 99
###xml 52 57 <span type="species:ncbi:9606">human</span>
Up-regulation of endothelin type B receptors in the human internal mammary artery in culture is dependent on protein kinase C and mitogen-activated kinase signaling pathways
###end article-title 99
###begin article-title 100
###xml 76 83 <span type="species:ncbi:9986">rabbits</span>
Alterations in endothelin B receptor sites in cavernosal tissue of diabetic rabbits: potential relevance to the pathogenesis of erectile dysfunction
###end article-title 100
###begin article-title 101
###xml 155 159 <span type="species:ncbi:10090">mice</span>
Corresponding distributions of increased endothelin-B receptor expression and increased endothelin-1 expression in the aorta of apolipoprotein E-deficient mice with advanced atherosclerosis
###end article-title 101
###begin article-title 102
###xml 72 80 <span type="species:ncbi:9606">patients</span>
Endogenous plasma endothelin concentrations and coronary circulation in patients with mild dilated cardiomyopathy
###end article-title 102
###begin article-title 103
Endothelin during cardiovascular surgery: the effect of diltiazem and nitroglycerin
###end article-title 103
###begin article-title 104
###xml 14 19 <span type="species:ncbi:9606">human</span>
Chemotaxis of human blood monocytes toward endothelin-1 and the influence of calcium channel blockers
###end article-title 104
###begin article-title 105
Constitutive endothelin-1 overexpression promotes smooth muscle cell proliferation via an external autocrine loop
###end article-title 105
###begin article-title 106
The effects of endothelin-1 on collagen type I and type III synthesis in cultured porcine coronary artery vascular smooth muscle cells
###end article-title 106
###begin article-title 107
###xml 111 119 <span type="species:ncbi:9606">patients</span>
Endothelin B receptors are functionally important in mediating vasoconstriction in the systemic circulation in patients with left ventricular systolic dysfunction
###end article-title 107
###begin article-title 108
Transcriptional regulated plasticity of vascular contractile endothelin ET(B) receptors after organ culture
###end article-title 108
###begin article-title 109
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human endothelin-B receptor gene. Structural organization and chromosomal assignment
###end article-title 109
###begin article-title 110
###xml 89 94 <span type="species:ncbi:9606">human</span>
Organization, structure, chromosomal assignment, and expression of the gene encoding the human endothelin-A receptor
###end article-title 110
###begin article-title 111
Cytokines induce increased endothelin ET(B) receptor-mediated contraction
###end article-title 111
###begin article-title 112
Anti-inflammatory strategies in hypertension: focus on COX-1 and COX-2
###end article-title 112
###begin article-title 113
###xml 64 69 <span type="species:ncbi:9606">human</span>
Angiotensin II receptor mRNA expression and vasoconstriction in human coronary arteries: effects of heart failure and age
###end article-title 113
###begin article-title 114
###xml 83 91 <span type="species:ncbi:9606">patients</span>
Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients
###end article-title 114
###begin article-title 115
Modulation of angiotensin II receptor expression during development and regression of hypoxic pulmonary hypertension
###end article-title 115
###begin article-title 116
###xml 95 102 <span type="species:ncbi:9986">rabbits</span>
Increased angiotensin II type 1 receptor expression in hypercholesterolemic atherosclerosis in rabbits
###end article-title 116
###begin article-title 117
###xml 93 96 <span type="species:ncbi:10116">rat</span>
High glucose concentration augments angiotensin II mediated contraction via AT1 receptors in rat thoracic aorta
###end article-title 117
###begin article-title 118
Regulation of vascular type 1 angiotensin receptors by cytokines
###end article-title 118
###begin article-title 119
C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle
###end article-title 119
###begin article-title 120
Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity
###end article-title 120
###begin article-title 121
Endothelial cell injury in cardiovascular surgery: the pathophysiology of vasomotor dysfunction
###end article-title 121
###begin article-title 122
Vascular and cardiac benefits of angiotensin receptor blockers
###end article-title 122
###begin article-title 123
Current status of bosentan for treatment of pulmonary hypertension
###end article-title 123
###begin article-title 124
###xml 92 96 <span type="species:ncbi:10090">mice</span>
Blockade of endothelin receptors markedly reduces atherosclerosis in LDL receptor deficient mice: role of endothelin in macrophage foam cell formation
###end article-title 124
###begin article-title 125
Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial
###end article-title 125

